Education
About Us
Working with TipRanks
Follow Us
LENSAR (LNSR)
NASDAQ:LNSR
LNSR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.80 - $17.31
Previous CloseN/A
Volume40.10K
Average Volume (3M)61.68K
Market Cap
$145.25M
Enterprise Value$153.02M
Total Cash (Recent Filing)$20.31M
Total Debt (Recent Filing)$2.33M
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Nov 06, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding11,934,784
10 Day Avg. Volume65,607
30 Day Avg. Volume61,683
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue2.62
Enterprise Value/Gross Profit5.56
Enterprise Value/Ebitda-12.71
Forecast
1Y Price Target
$12.50Price Target Upside2.71% Upside
Rating ConsensusHold
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
AcquisitionThe announced acquisition by Alcon is seen as a positive outcome for both Lensar and Alcon, with Lensar experiencing strong adoption of its ALLY System in the cataract surgery market.
Market ExpansionLNSR highlighted that ~75% of US FY24 placements have come from new customers, indicating strong market expansion and competitive positioning.
Bears Say
Growth ChallengesLensar is required to achieve substantial procedure growth to meet the terms of the acquisition agreement, which may pose challenges.
ValuationThe stock is rated as Neutral because the implied takeout value is seen as fairly valued, indicating limited upside potential.
LENSAR News
LNSR FAQ
What was LENSAR’s price range in the past 12 months?
LENSAR lowest stock price was $3.80 and its highest was $17.31 in the past 12 months.
What is LENSAR’s market cap?
LENSAR’s market cap is $145.25M.
When is LENSAR’s upcoming earnings report date?
LENSAR’s upcoming earnings report date is Nov 06, 2025 which is in 61 days.
How were LENSAR’s earnings last quarter?
LENSAR released its earnings results on Aug 07, 2025. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.019 by -$0.131.
Is LENSAR overvalued?
According to Wall Street analysts LENSAR’s price is currently Undervalued.
Does LENSAR pay dividends?
LENSAR does not currently pay dividends.
What is LENSAR’s EPS estimate?
LENSAR’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does LENSAR have?
LENSAR has 11,934,784 shares outstanding.
What happened to LENSAR’s price movement after its last earnings report?
LENSAR reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.019. Following the earnings report the stock price went down -1.458%.
Which hedge fund is a major shareholder of LENSAR?
Currently, no hedge funds are holding shares in LNSR
LENSAR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$12.50 (2.71% Upside)
$12.50 (2.71% Upside)
Blogger Sentiment
Bullish
LNSR Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 48.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 5.3%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
174.96%
12-Months-Change
Fundamentals
Return on Equity
-350.22%
Trailing 12-Months
Asset Growth
14.67%
Trailing 12-Months
Company Description
LENSAR
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company was incorporated in 2004 and is headquartered in Orlando, Florida.
Technical Analysis
Ownership Overview
41.02% Insiders
8.12% Mutual Funds
18.66% Other Institutional Investors
25.61% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---